The previous study has unveiled that the co-administration of ursolic acid and sorafenib exhibits a synergistic impact by upregulating ROS levels and downregulating the expression of SLC7A11 in gastric cancer and colon cancer cells 20. Here, SLC7A11 is linked to colonic neoplasm.